Novel Synthetic Nucleic Acid Technology Development (R43/R44)( Clinical Trial not allowed)

The summary for the Novel Synthetic Nucleic Acid Technology Development (R43/R44)( Clinical Trial not allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Novel Synthetic Nucleic Acid Technology Development (R43/R44)( Clinical Trial not allowed): This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications from small businesses to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Large progress in this area has the potential to catalyze scientific advances relevant to the mission of NIH, NHGRI and the field of genomics.

Federal Grant Title:	Novel Synthetic Nucleic Acid Technology Development (R43/R44)( Clinical Trial not allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HG-20-016
Type of Funding:	Grant
CFDA Numbers:	93.350
CFDA Descriptions:	Information not provided
Current Application Deadline:	February 4th, 2022
Original Application Deadline:	February 4th, 2022
Posted Date:	March 19th, 2020
Creation Date:	March 19th, 2020
Archive Date:	March 6th, 2022
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	October 5th, 2020

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-016.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Single Source for the Continuation of the Data Management and Coordinating Center (DMCC) f...; • Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed); • Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Dis...; • Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not...; • Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science ...; • Limited Competition: Revision Applications to Advance Evidence-Based Research Related to P...; • A Pre-application for the NIH-Industry Pilot Program: Discovering New Therapeutic Uses for...; • Limited Competition for NIH-Industry Pilot Program: Discovering New Therapeutic Uses for E...
More Grants from the National Institutes of Health: • The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Preven...; • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional); • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...